Joshua Leitner, MD
Interventional Cardiology · Asheville, NCNPI 1992729388
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,133 of the $8,217 with a category attached, or 62.5%. 18 manufacturers reported payments, led by Abbott at 33.0% of the total.
Across 129 payments — averaging $63.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Medtronic$405
- Abiomed$155
- Pfizer$132
- plus $540 from 12 others
Across 32 payments — averaging $5767.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$185K
What the payments were for
- Travel & lodging$3,08438%
- Food & beverage$5,13362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $2,714 |
| Edwards Lifesciences | 18 | $2,455 |
| Boston Scientific | 26 | $1,816 |
| Medtronic(2 entities) | 11 | $405 |
| Abiomed | 2 | $155 |
| Pfizer | 6 | $132 |
| Boehringer Ingelheim | 1 | $125 |
| Philips North America LLC | 2 | $105 |
| Alnylam Pharmaceuticals Inc. | 1 | $89 |
| Cardiovascular Systems Inc. | 1 | $38 |
| Cardiva Medical, Inc. | 2 | $35 |
| Biosense Webster, Inc. | 1 | $33 |
| Merck | 1 | $24 |
| Atricure, Inc. | 1 | $20 |
| Surmodics, Inc. | 1 | $20 |
| Davol Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,559
- Watchman$782
- WATCHMAN FLX$383
- SAPIEN 3 Ultra RESILIA$246
- Mitra Clip system$179
- PORTICO$175
- WATCHMAN Access System$158
- AMPLATZER AMULET$147
- COROFLOW$135
- COREVALVE EVOLUT R$132
- JARDIANCE$125
- MitraClip$111
- AMPLATZER$110
How this compares
$8,217 in reported general payments places this provider in the 60th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 208 | $217,224 |
| JardianceEmpagliflozin | 106 | $92,623 |
| EntrestoSacubitril/Valsartan | 68 | $71,090 |
| XareltoRivaroxaban | 42 | $50,068 |
| Repatha SureclickEvolocumab | 58 | $49,491 |
| Metoprolol Succinate | 314 | $3,759 |
| Atorvastatin Calcium | 340 | $3,075 |
| Dofetilide | 18 | $2,787 |
| Diltiazem 12hr ErDiltiazem Hcl | 15 | $2,650 |
| ClopidogrelClopidogrel Bisulfate | 151 | $1,607 |
| Metoprolol Tartrate | 292 | $1,531 |
| Rosuvastatin Calcium | 155 | $1,496 |
| Losartan Potassium | 162 | $1,478 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 115 | $1,375 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $132 | $217,224208 claims |
| Boehringer IngelheimJardiance | $125 | $92,623106 claims |
| NovartisEntresto | $17 | $71,09068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Asheville
- Jan PattanayakAsheville$212K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Steven FilbyPinehurst$442K
- Naveed RajperStatesville$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.